Cost-utility analysis of vagus nerve stimulators for adults with medically refractory epilepsy

Seizure

Volumn 12, Issue 5, 2003, Pages 249-256

  Forbes, Raeburn B ^a   Macdonald, Shirley ^b   Eljamel, Sam ^b   Roberts, Richard C ^b  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Costs; Economic evaluation; Epilepsy; Vagus nerve stimulator

Indexed keywords

LAMOTRIGINE; TOPIRAMATE; VIGABATRIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST UTILITY ANALYSIS; DISEASE CONTROL; EPILEPSY; EXPERIMENTAL MODEL; HEALTH CARE COST; HEALTH CENTER; HEALTH STATUS; HUMAN; IMPLANTATION; LENGTH OF STAY; MEDICAL INSTRUMENTATION; MEDICAL LITERATURE; META ANALYSIS; MORBIDITY; PATIENT SELECTION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; TASK PERFORMANCE; VAGUS NERVE STIMULATION;

EID: 0038760035     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1059-1311(02)00270-4     Document Type: Article

References (31)

1. Current results and perspectives on vagus nerve stimulation for the treatment of epilepsy. In: Satellite Symposium of the 22nd International Epilepsy Congress, 28 June 1997 (Ed. P. Chauvel). Dublin, Blackwell Science, 1997: p. 46.
2. Robinson, R. Economic evaluation and health care. The policy context. British Medical Journal 1993; 307: 994-996.
3. Fisher, R. S., Krauss, G. L., Ramsay, E., Laxer, K. and Gates, J. Assessment of vagus nerve stimulation for epilepsy: report of the Therapeutics and Technology Subcommittee of the American Academy of Neurology. Neurology 1997; 49: 293-297.
4. Ben-Menachem, E., Manon-Espaillat, R., Ristanovic, R., Wilder, B. J., Stefan, H., Mirza, W. et al. First International Vagus Nerve Stimulation Study Group. Vagus nerve stimulation for treatment of partial seizures. 1. A controlled study of effect on seizures. Epilepsia 1994; 35: 616-626.
5. Handforth, A., DeGiorgio, C. M., Schachter, S. C., Uthman, B. M., Naritoku, D. K., Tecoma, E. S. et al. Vagus nerve stimulation therapy for partial-onset seizures. A randomized active-control trial. Neurology 1998; 51: 48-55.
6. Current results and perspectives on vagus nerve stimulation for the treatment of epilepsy. In: Proceedings of a Satellite Symposium Sponsored by Cyberonics and held during the 22nd International Epilepsy Congress, Dublin, 28 June 1997 (Ed. P. Chauvel). Oxford, Blackwell Science, 1998.
7. van Hout, B., Gagnon, D., Souetre, E., Ried, S., Remy, C., Baker, G. et al. Relationship between seizure frequency and costs and quality of life of patients with partial epilepsy in France, Germany and the United Kingdom. Epilepsia 1997; 38: 1221-1226.
8. Jacoby, A., Buck, D., Baker, G., McNamee, P., Graham-Jones, S. and Chadwick, D. Uptake and costs of care for epilepsy: findings from a UK regional study. Epilepsia 1998; 39: 776-786.
9. Cockerell, O. C., Hart, Y. M., Sander, J. W. A. S. and Shorvon, S. The cost of epilepsy in the United Kingdom: an estimation based on the results of two population based studies. Epilepsy Research 1994; 18: 249-260.
10. Begley, C. E., Annegers, J. F., Lairson, D. R., Reynolds, T. F. and Hauser, W. A. Cost of epilepsy in the United States: a model based on incidence and prognosis. Epilepsia 1994; 35: 1230-1243.
11. Selai, C., Smith, K. and Trimble, M. R. Adjunctive therapy in epilepsy: a cost-effectiveness comparison of two AEDs. Seizure 1999; 8: 8-13.
12. Malmgren, K., Hedstrom, A., Granqvist, R., Malmgren, H. and Ben-Menachem, E. Cost analysis of epilepsy surgery and of vigabitrin treatment in patients with refractory partial epilepsy. Epilepsy Research 1996; 25: 199-207.
13. Boon, P., Vonck, K., Vandekerckhove, T. and D'Have, M. Vagus nerve stimulation for medically refractory epilepsy; efficacy and cost-benefit analysis. Acta Neurochirurgica Wien 1999; 141: 447-453.
14. Vachris, M. and Thomas, J. International price comparisons based upon purchasing power parity. Monthly Labor Review 1999; October: 3-12.
15. Messori, A., Trippoli, S., Becagli, P., Cincotta, M., Labbate, M. G. and Zaccara, G. Adjunctive lamotrigine therapy in patients with refractory seizures: a lifetime cost-utility analysis. European. Journal of Clinical Pharmacology 1998; 53: 421-427.
16. Torrance, G. W. Measurement of health state utilities for economic appraisal. Journal of Health Economics 1986; 5: 1-30.
17. Baker, G. A., Smith, D. F., Dewey, M., Jacoby, A. and Chadwick, D. W. The initial development of a health related quality of life model as an outcome measure in epilepsy. Epilepsy Research 1993; 16: 65-81.
18. The EUROQOL Group. EuroQol - a new facility for the measurement of health related quality of life. Health Policy 1990; 16: 199-208.
19. Dolan, P., Gudex, C., Kind, P. and Williams, A. A social tariff for EuroQol: results from a UK general population survey. Discussion Paper No. 138. York, University of York, 1995.
20. Donaldson, C. and Shackley, P. Economic studies. In: Oxford Textbook of Public Health, 3rd edn. (Eds R. Detels, W. W. Holland, J. McEwen and G. S. Omenn). Oxford, Oxford University Press, 1995.
21. McGuire, A., Henderson, J. and Mooney, G. The Economics of Healthcare. London, Routledge, 1992.
22. Drummond, M., Stoddart, G. and Torrance, G. Methods for the Economic Evaluation of Healthcare Programmes. Oxford, Oxford University Press, 1987.
23. George, R., Salinsky, M., Kuzniecky, R., Rosenfeld, W., Bergen, D., Tarver, W. et al. Vagus nerve stimulation for treatment of partial seizures. 3. Long-term follow-up on first 67 patients exiting a controlled study. Epilepsia 1994; 35: 637-643.
24. Donaldson, C. and Gerard, K. Economics of Health Care Financing: The Visible Hand. Basingstoke, The Macmillan Press Ltd, 1993.
25. Elferink, A. J. A. and Zwieten-Boot, B. J. V. New anticonvulsant drugs. British Medical Journal 1997; 314: 602.
26. Markowitz, M. A., Mauskopf, J. A. and Halpern, M. T. Cost-effectiveness model of adjunctive lamotrigine for the treatment of epilepsy. Neurology 1998; 51: 1026-1033.
27. Langfitt, J. T. Cost-effectiveness of anterotemporal lobectomy in medically intractable complex partial epilepsy. Epilepsia 1997; 38: 154-163.
28. King, J. T., Sperling, M. R., Justice, A. C. and O'Connor, M. J. A cost-effectiveness analysis of anterior temporal lobectomy for intractable temporal lobe epilepsy. Journal of Neurosurgery 1997; 87: 20-28.
29. Laupacis, A., Feeny, D., Detsky, A. S. and Tugwell, P. X. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Canadian Medical Association Journal 1992; 146: 473-481.
30. Waugh, N. Grading of scientific evidence - a discussion paper from SHPIC. Health Bulletin 1999; 57: 53-63.
31. Forbes, R. B., Lees, A., Waugh, N. and Swingler, R. J. Population based cost-utility study of interferon beta 1b for secondary progressive multiple sclerosis. British Medical Journal 1999; 319: 1529-1533.